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Primary sclerosing Cholangitis: 
epidemiology, Genetics, Diagnosis, 
and Current Management
Eric Gochanour, M.D.,* Channa Jayasekera, M.D.,†  
and Kris Kowdley, M.D.*
Primary sclerosing cholangitis (PSC) is a rare, idio-
pathic, and progressive biliary tract disease that can 
lead to liver fibrosis and cirrhosis. PSC is characterized 
by inflammation and destruction of intrahepatic and ex-
trahepatic bile ducts, leading to progressive hepatic fi-
brosis.1 The etiology of PSC is unknown, although several 
genes are associated with its development and clinical 
course.2,3 There is a strong association between inflam-
matory bowel disease (IBD) of the colon and PSC.1,2 An 
overlap syndrome of autoimmune hepatitis and PSC is 
an additional, well-established presentation, particularly 
in younger patients. The diagnosis of PSC relies heavily 
on characteristic cholangiographic features in the setting 
of cholestatic liver enzyme abnormalities.2 Patients with 
PSC are at increased risk for cholangiocarcinoma and 
gallbladder cancer, as well as colon cancer in those with 
concurrent IBD.4 Screening for malignancies involving the 
gallbladder, bile ducts, and colon is therefore a critical 
component of PSC management. Liver transplantation is 
by far the most effective treatment, although a posttrans-
plant recurrence rate of approximately 20% is reported. 
This review aims to highlight the most salient aspects of 
identifying and managing this unique cholestatic liver 
disease.
ePiDeMiOlOGY
PSC is a rare disorder with regional variation in preva-
lence.3 The prevalence in the United States is estimated 
to be 1 to 16 per 100,000.1 An estimated 80% of pa-
tients diagnosed with PSC have concurrent IBD.2 There 
is a 2:1 male predominance when PSC is associated with 
IBD and a slight female predominance in the absence of 
IBD (Table 1).1 Average age at diagnosis is typically 30 to 
40 years old.1 In patients with IBD, the prevalence rate of 
PSC is estimated to be approximately 5%.3
Abbreviations: ERC, endoscopic retrograde cholangiography; IBD, inflammatory bowel disease; MRC, magnetic resonance 
cholangiography; PSC, primary sclerosing cholangitis.
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GeneTiCs
The pathogenesis of PSC remains unclear, although 
multiple genes have been implicated in its development.3 
An immunologically mediated process is supported by 
known associations with human leukocyte antigens.3 
Another theory involves bacterial translocation to the 
biliary tree based on an animal model of bacterial over-
growth and link with ulcerative colitis.3,4 Certain gene 
mutations including cystic fibrosis transmembrane recep-
tor (CFTR) mutations have also been associated with the 
development of PSC.3,4
DiaGnOsis
Patients with PSC are often asymptomatic early in the 
disease course; usually they are identified through a per-
sistent cholestatic pattern of elevated liver enzymes.2 
Fatigue and pruritus are common symptoms, but many 
patients are asymptomatic. Biliary tract obstruction may 
lead to acute pruritus and/or cholangitis, presenting with 
jaundice, fever, and abdominal pain. Patients with PSC-
IBD may present with abnormal bowel habits, abdominal 
pain, and intestinal bleeding, with concurrent liver enzyme 
abnormalities.
The differential diagnosis of PSC includes secondary 
sclerosing cholangitis, immunoglobulin G4–associated 
cholangitis, autoimmune hepatitis, primary biliary cholan-
gitis, ischemic cholangiopathy, papillary tumors, cholan-
giocarcinoma, cholangiolithiasis, and HIV cholangiopathy.3 
These causative factors should be evaluated during the 
diagnostic workup.
Liver biopsy is usually unnecessary in diagnosing PSC, 
but it is helpful to evaluate PSC-autoimmune hepatitis 
overlap syndrome and small-duct PSC.3 Characteristic fea-
tures of PSC on histology include concentric periductal 
“onion skinning” fibrosis, although this distinctive feature 
is insensitive.3 Similarly, there are no known sensitive sero-
logical assays for PSC.
THe rOle OF iMaGinG in PsC
Given the limitations of liver histology and absence of 
sensitive serological assays, it is essential to perform chol-
angiography when PSC is suspected. Magnetic resonance 
cholangiography (MRC) is now recommended by all major 
professional societies as the initial diagnostic modality of 
choice2,3,5,6 (Table 2).
Even though MRC is highly sensitive and specific (0.86 
and 0.94, respectively) in detecting the multifocal biliary 
stricturing and peripheral pruning phenotype of large-
duct PSC, indeterminate cases warrant consideration of 
endoscopic retrograde cholangiography (ERC), which re-
mains the reference standard for cholangiography (Fig. 1). 
Isolated involvement of peripheral ductules (small-duct 
TaBle 1. PsC ePiDeMiOlOGY
Characteristics
Sex: Men (2:1)
Age at Diagnosis: Fourth to fifth decade of life
IBD in PSC: 80%
PSC in IBD: 5%
TaBle 2. DiaGnOsinG PsC
MRCP ERCP Liver Biopsy
Noninvasive Greater sensitivity Used to rule out  
overlapping conditions
Less expensive Allows for therapeutic 
intervention
No radiation exposure
Eliminates risk for 
pancreatitis
FIG 1 Endoscopic retrograde cholangiography demonstrating 
focal strictures and dilations creating characteristic “beading” 
appearance of intrahepatic bile ducts.
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PSC) is seen in less than 10% of cases, necessitating liver 
biopsy because both MRC or ERC are insensitive for small-
duct changes.7 Although useful for diagnosis, neither 
baseline nor serial cholangiographic features predict dis-
ease progression or prognosis in PSC.
The increased risk for clinically significant biliary 
obstruction, cholelithiasis, hepatolithiasis, cholangiocellu-
lar dysplasia and cholangiocarcinoma, hepatocellular car-
cinoma, polyps and cancer of the gallbladder, and colon 
cancer drives the vital role of regular imaging in the long-
term management of PSC (Table 3).
Screening for Malignancy and Premalignant States
Despite the modest positive predictive values, most pro-
fessional societies and expert opinion support screening for 
cholangiocarcinoma with ultrasonography, MRC, and ERC, 
with or without serum CA 19-9 every 6 to 12 months.2,3,5 
Annual ultrasonography is the recommended modal-
ity for gallbladder polyp and cancer screening. As with 
patients without PSC, the presence of advanced (stage 3) 
liver fibrosis or cirrhosis warrants hepatocellular carcinoma 
screening every 6 months, with ultrasonography, com-
puted tomography, or magnetic resonance imaging, with 
or without serum alpha-fetoprotein. Elastography modali-
ties (e.g., FibroScan, magnetic resonance elastography) for 
fibrosis staging in PSC require further validation. Even in 
asymptomatic individuals, colonoscopy to screen for IBD is 
recommended in all patients at PSC diagnosis. Presence of 
concurrent PSC and IBD warrants colon cancer screening 
with colonoscopy every 1 to 2 years.2,5 European guide-
lines additionally recommend colonoscopy with random 
colonic biopsies for IBD screening every 5 years in patients 
with PSC who do not have concurrent IBD.5
Imaging Directed by Clinical Features
Differentiating malignant and benign dominant biliary 
strictures is difficult. Nevertheless, the development of 
dominant biliary strictures should prompt an exhaustive 
evaluation for cholangiocarcinoma. Despite very high speci-
ficity, sensitivity for cholangiocarcinoma of brush cytology 
obtained on ERC is only 43%.8 The addition of fluorescent 
in situ hybridization increases sensitivity to 68%, although 
specificity decreases to 70%.8,9 Pooled data from small stud-
ies of endoscopic retrograde cholangioscopy with targeted 
biopsy demonstrate a 65% sensitivity and 97% specificity.10
CUrrenT ManaGeMenT
There are no approved pharmacological therapies for 
PSC. Ursodeoxycholic acid is the best studied, although 
the role of this therapy in PSC remains unclear.3 High-
dose ursodeoxycholic acid (>28 mg/kg/day) is associated 
with increased adverse clinical outcomes and should be 
avoided.11 Despite enthusiasm about its use as a possible 
therapy for PSC, recent studies with oral vancomycin have 
not shown significant benefit, and randomized clinical tri-
als are needed.3 Patients with decompensated cirrhosis 
caused by PSC or with refractory cholangitis may be best 
treated with liver transplantation. Liver transplantation has 
shown success for selected patients with hilar cholangio-
carcinoma caused by PSC.12 Recurrent PSC is estimated to 
occur in approximately 20% of patients.3
As with other cholestatic liver diseases, osteopenia may 
be a complication of PSC, and bone density screening at 
diagnosis and at 2- to 4-year intervals is suggested.3 Fat-
soluble vitamin deficiencies may occur.3
PrOGnOsis
The disease course of PSC is highly variable. Serum 
alkaline phosphatase levels <1.5× upper limit of normal 
have been associated with improved survival in patients 
with PSC,13 whereas patients with alkaline phosphatase 
levels ≥2.4× upper limit of normal are more likely to die or 
require liver transplantation.14
COnClUsiOn
PSC is a rare idiopathic cholestatic liver disease with no 
approved treatment, although a number of agents are cur-
rently showing promise in clinical trials. The disease course is 
variable, and management is focused on mitigating several 
life-threatening complications, including hepatic and extra-
hepatic malignancies, with emphasis on early consideration 
of liver transplantation in appropriately selected patients; 
liver transplantation is an effective treatment for end-stage 
liver disease. Disease recurrence has been reported but does 
not reduce favorable long-term outcomes.
TaBle 3. COMPliCaTiOns OF PsC
Cholangitis
Gastrointestinal malignancies
Fat-soluble vitamin deficiencies
Bone diseases
Cirrhosis and portal hypertension
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